Additional Resources | Daily COPD Medication

Take the test to see what impact COPD may be having on your life. Discuss your test score with your doctor or nurse.
Take the test
More information and support for people with COPD is available from:
Visit page
Visit page

Download

Any information provided on this website should be discussed with a health care professional (HCP) and does not replace a HCP’s advice.

Find out more about COPD:

References: 1. Anoro Ellipta Data Sheet, GSK New Zealand, available at www.medsafe.govt.nz 2. Anoro Ellipta Consumer Medical Information, GSK New Zealand, available at www.medsafe.govt.nz 3. PHARMAC Pharmaceutical Schedule March 2022. Available at https://bit.ly/2VQHXQB 4. Town, I., Taylor, R., Garrett, J., & Patterson, J. (2003). The Burden of COPD in New Zealand. Available at https://bit.ly/3gsPc97 5. Lung Foundation Australia (2020). The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2020 6. Kirby SY COPD 2016;13;167-175 7. Grant AC International Society for Aerosols in Medicine 2015;28;474-85 8. Prime D; Journal of aerosol medicine and pulmonary drug delivery; 2015;28;486-497

Anoro Ellipta (umeclidinium bromide/vilanterol trifenatate inhaler 62.5/25mcg per inhalation) is a Prescription Medicine. Anoro Ellipta is used for long-term regular treatment to relieve symptoms in adults with Chronic Obstructive Pulmonary Disease (COPD). Anoro Ellipta is a fully funded medicine. Use strictly as directed. Do not take Anoro Ellipta to treat asthma or to relieve acute symptoms. Always carry your reliever inhaler. This medicine has risks and benefits. Tell your doctor: If you have severe milk-protein allergy, or you have demonstrated hypersensitivity to either umeclidinium, vilanterol trifenatate or any of the excipients in Anoro Ellipta, or if you are taking other medicines or herbal remedies, you have heart problems or high blood pressure, liver or thyroid problems, epilepsy or other seizure disorders, difficulty passing urine, a blockage in your bladder or other bladder problems, chronic or untreated infection, narrow-angle glaucoma or diabetes. Side Effects: Sore throat with or without a runny nose, cough, constipation, dry mouth, painful and frequent urination, pain and irritation in the back of the mouth and throat, infection of the upper airways, pain of the sinuses.If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional. For more information see Anoro Ellipta Consumer Medicine Information at www.medsafe.govt.nz. Normal doctor's charges apply. Ask your doctor if Anoro Ellipta is right for you. Trademarks are owned by or licensed to the GSK group of companies. ©2022 GSK group companies or its licensor. Anoro Ellipta was developed in collaboration with Innoviva Inc. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.
TAPS NP18424-PM-NZ-UCV-WCNT-200003. Date of Approval: 09 2022 Date of Expiry: 09 2024.

Where can I find out more about my COPD?

More information and support for people with COPD is available from:

Any information provided on this website should be discussed with a health care professional (HCP) and does not replace a HCP’s advice.